过去一年中添加的文章，按日期排序
… with IMP321 (eftilagimod alpha) in combination with PD-L1 inhibitor (avelumab) for metastatic or unresectable locally advanced urothelial carcinoma (UC)—IKF-s614.
I Tsaur, MPJK Brandt, E Goekkurt, V Grünwald, D Pink… - 2024 - ascopubs.org
41 天前 - … -free platinum-based chemotherapy for locally advanced (LA) or mUC. Further …
, nivolumab) achieved approval or showed promising results for treatment of different patient …
, nivolumab) achieved approval or showed promising results for treatment of different patient …
Evolution of front-line immunotherapy for metastatic urothelial cancer
AO Siefker-Radtke, M Desai - The Lancet Oncology, 2024 - thelancet.com
210 天前 - … in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final
… of 304 patients with nivolumab combination therapy versus 131 (43·1%) of 304 patients with …
… of 304 patients with nivolumab combination therapy versus 131 (43·1%) of 304 patients with …
2369P Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
BA McGregor, MT Campbell, J Huang… - Annals of …, 2023 - annalsofoncology.org
283 天前 - … Eligible pts had locally advanced unresectable or metastatic BCVH (>90% [JB1]
variant histology) and ECOG performance status ≤2. Prior immunotherapy was prohibited; no …
variant histology) and ECOG performance status ≤2. Prior immunotherapy was prohibited; no …
Unanticipated pathological clearance in two cases of clinical T4b dMMR/MSI-h advanced colorectal cancer: the potential of immune checkpoint inhibitors despite …
D Nakamura, T Yanagita, Y Fujii, K Watanabe… - Surgical Case …, 2024 - Springer
313 天前 - … after failure of chemotherapy followed by combination treatment with nivolumab and
… pCR after neoadjuvant chemoradiation in patients with locally advanced rectal cancer [37]. …
… pCR after neoadjuvant chemoradiation in patients with locally advanced rectal cancer [37]. …